Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 3:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Non-specific Therapy Clear all
Completed Not applicable Interventional Accepts healthy volunteers

PBM or Dry Float Therapy on Sleep Quality in Middle-aged and Elderly

NCT05963555
View directory record Official record
Conditions
Sleep Quality
Interventions
NovoThor, VieLight, ZeroBody
Device
Lead sponsor
West Virginia University
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Symptom Experience Study in Persons With Non-Small Cell Lung Cancer

NCT01786187
View directory record Official record
Conditions
Lung Cancer
Interventions
Light Physical Activity, Symptom Experience Report
Behavioral · Other
Lead sponsor
Michigan State University
Other
Eligibility
21 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
East Lansing, Michigan • Grand Rapids, Michigan • Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2019 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

NCT03928847
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Epigallocatechin-3-gallate (EGCG)
Drug
Lead sponsor
Hal Chapman
Other
Eligibility
40 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 21, 2026, 3:38 AM EDT
Not yet recruiting Not applicable Interventional

Comparing Non-Medicine Strategies for Improving Low Back Pain

NCT07679178
View directory record Official record
Conditions
Chronic Low-back Pain (cLBP), High-Impact Chronic Pain (HICP)
Interventions
ENCompaSS (Education, Navigated Care, and Supported Self-Management) with VA Stepped Usual Care
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Auditory-Perceptual Training Via Telepractice

NCT04858035
View directory record Official record
Conditions
Speech Sound Disorder
Interventions
Perceptual training, Production training
Behavioral
Lead sponsor
Montclair State University
Other
Eligibility
9 Years to 15 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Upper Montclair, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 21, 2026, 3:38 AM EDT
Withdrawn Not applicable Interventional

A Effectiveness Trial of Early Hemodynamic Support in Patients Demonstrating a Low Systolic Blood Pressure

NCT01654835
View directory record Official record
Conditions
Intraoperative Low Blood Pressure
Interventions
low blood pressure alert, standard of care
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Phase 1Phase 2 Interventional

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

NCT04673617
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine
Drug
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Birmingham, Alabama • Tucson, Arizona • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 21, 2026, 3:38 AM EDT
Recruiting No phase listed Observational

Proton Therapy Patient Registry

NCT02986048
View directory record Official record
Conditions
Treatment With Proton Beam Radiation Therapy
Interventions
Proton Beam Therapy
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 21, 2026, 3:38 AM EDT
Recruiting Phase 2 Interventional

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

NCT07242638
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata
Interventions
Abrocitinib
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Addressing Racial/Ethnic Tobacco Health Disparities Via Group Intervention

NCT02511236
View directory record Official record
Conditions
Smoking Cessation
Interventions
Group Cognitive Behavioral Therapy, General Health Education, Transdermal Nicotine Patch
Behavioral · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
2
States / cities
Coral Gables, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 21, 2026, 3:38 AM EDT
Terminated Phase 2 Interventional Results available

Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall

NCT00089544
View directory record Official record
Conditions
Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7
Interventions
Dacarbazine, Doxorubicin Hydrochloride, Filgrastim, Ifosfamide, Laboratory Biomarker Analysis, Radiation Therapy, Thalidomide, Therapeutic Conventional Surgery
Drug · Biological · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

NCT01171898
View directory record Official record
Conditions
Prostate Cancer
Interventions
ARN-509 (Phase 1), ARN-509 (Phase 2)
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02574078
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Bevacizumab, Pemetrexed, Best Supportive Care, nab-Paclitaxel, Paclitaxel, Docetaxel, Gemcitabine, Erlotinib, Crizotinib, Carboplatin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
133
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 21, 2026, 3:38 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeting Specific Brain Networks to Treat Specific Symptoms in Depression

NCT05523817
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Intermittent Theta Burst Stimulation (iTBS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Not applicable Interventional Results available

Increasing Engagement in Evidence-Based PTSD Therapy for Primary Care Veterans

NCT01984515
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
Referral Management System
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT02728050
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Cladribine, Cytarabine, Filgrastim, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Mitoxantrone, Sorafenib
Drug · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Not applicable Interventional

Pilot Study on Energy Therapy or Massage to Reduce Fatigue

NCT02758756
View directory record Official record
Conditions
Fatigue
Interventions
Massage, Reiki
Other
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Not applicable Interventional Results available

Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation

NCT03037983
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Repetitive transcranial magnetic stimulation, Sham
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)

NCT00744042
View directory record Official record
Conditions
Hypophosphatasia (HPP)
Interventions
asfotase alfa
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 36 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Wilmington, Delaware • Springfield, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2019 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Phase 1 Interventional

SU5416 in Treating Patients With Advanced Solid Tumors

NCT00005642
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
semaxanib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Sep 21, 2026, 3:38 AM EDT
Withdrawn Phase 4 Interventional

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

NCT04066088
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Placebo, Guanfacine extended release (GXR)
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 21, 2026, 3:38 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT03075696
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Glofitamab, Obinutuzumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
6
States / cities
Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 21, 2026, 3:38 AM EDT
Recruiting Early Phase 1 Interventional

Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma

NCT05632562
View directory record Official record
Conditions
High Grade Glioma
Interventions
O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
10 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 21, 2026, 3:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations

NCT01156610
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Tobacco Treatment
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 21, 2026, 3:38 AM EDT